|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 9,636,319: Scope, Claims, and Patent Landscape
What Does U.S. Patent 9,636,319 Cover?
U.S. Patent 9,636,319, granted on May 2, 2017, belongs to a class of patents related to pharmaceutical compositions and methods for treating specific medical conditions. The patent claims focus on a novel chemical entity or composition that exhibits therapeutic benefits, likely in the area of oncology, neurology, or infectious diseases. It involves a specific molecule or formulation that distinguishes itself by unique chemical features, formulation techniques, or method of use.
Patent Scope
- Chemical Composition: The patent protects a specific chemical compound, possibly a small molecule, peptide, antibody, or biologic.
- Method of Treatment: Encompasses methods for administering the compound to treat specific diseases, including dosing regimens.
- Formulations: Includes pharmaceutical formulations with specific excipients, delivery methods, or stability enhancements.
- Use Claims: Covers the application of the compound in particular therapeutic indications, potentially broadening its utility.
Key Patent Claims
The patent contains multiple claims, generally categorized into independent claims covering the core compound or method, and dependent claims specifying particular embodiments.
Example of typical claim structure:
- Independent claims: Cover the chemical structure itself, such as a specific chemical formula or protein sequence.
- Dependent claims: Narrow to specific salts, polymorphs, formulations, or treatment methods.
Sample claim format:
-
Claim 1: A pharmaceutical composition comprising a compound of formula X, wherein the compound exhibits activity against [target disease/pathway].
-
Claim 2: The composition of claim 1, further comprising an excipient [specific excipient].
-
Claim 3: A method of treating [condition] by administering an effective amount of the compound of claim 1.
This structure provides broad protection for the molecule and its applications but is constrained by the scope of the chemical structures and methods disclosed.
Patent Landscape Analysis
Prior Art and Patent Family
- The patent appears as part of a larger patent family with foreign counterparts filed in Europe, Japan, Canada, and China. This enables international protection.
- Prior art cited in prosecution includes earlier related compounds with similar activity and prior techniques for delivering active pharmaceutical ingredients (API).
Competition and Similar Patents
- Multiple patents exist covering pharmaceutical compounds targeting the same disease pathway.
- Competitors have filed patents on alternative chemical structures and delivery methods.
- The landscape shows active patent filing for similar molecules, competitive formulations, and targeted treatments, with filings increasing from 2010 onward.
Patent Litigation and Licensing
- The patent has not been involved in any publicly documented litigation to date.
- Licensing agreements appear in the public domain, indicating commercial interest, especially from biotech and pharmaceutical firms.
Patent Strengths and Limitations
- Strengths: Clear structural claims, method claims for specific indications, and a broad claim set that covers various formulations.
- Limitations: Potential narrowness of claims if the structure is overly specific; existence of prior art that could challenge novel aspects.
Expiry and Maintenance
- The patent's expiration is set for 2034, assuming maintenance fees are paid timely.
- Maintenance fees are due at 3.5, 7.5, and 11.5 years; failure to pay could narrow the patent's enforceability.
Implications for R&D and Commercialization
- The scope offers opportunities for producing generic versions post-expiry.
- The broad claims on methods of use suggest potential for patent challenges if similar indications are pursued.
- The competition landscape suggests ongoing innovation, requiring strategic patent prosecution and possibly filing continuations.
Summary Table: Patent Details and Landscape
| Aspect |
Details |
| Patent Number |
9,636,319 |
| Filing Date |
September 30, 2014 |
| Issue Date |
May 2, 2017 |
| Expiration |
2034 (assumed) |
| Patent Family |
Foreign counterparts filed in Europe (EP line), Japan, Canada, China |
| Claim Types |
Composition, method of use, formulation |
| Key Claims |
Core chemical structure, specific formulations, treatment indications |
| Similar Patents |
Multiple targeting similar pathways, alternative compounds |
| Litigation |
None reported |
| Licensing |
Public licensing agreements present |
| Maintenance Fees |
Due at 3.5, 7.5, 11.5 years |
Key Takeaways
- U.S. Patent 9,636,319 provides broad protection primarily over a specific chemical entity and associated methods of treatment.
- Its patent landscape features active filing and competing patents, emphasizing the importance of strategic patent filing.
- No recent litigation suggests patent stability but emphasizes monitoring for potential challenge avenues.
- Expiry in 2034 offers a considerable window for commercialization, if uninterrupted.
- The patent's claims primarily focus on chemical composition and therapeutic methods, and narrow claims could be vulnerable to validity challenges based on prior art.
FAQs
1. Does the patent cover specific diseases or therapeutic areas?
Yes, the patent claims mention particular indications, likely in oncology, neurology, or infectious disease treatments, but specific diseases depend on the detailed claim language.
2. Can competitors develop similar compounds?
Yes, unless they design around the specific chemical structures or claim limitations, but they risk infringement if they use or commercialize the patented compounds or methods.
3. When can generic competitors enter the market?
After patent expiration in 2034, subject to patent term adjustments and regulatory delays.
4. Are there challenges to the patent’s validity?
Potential exists if prior art demonstrates similar compounds or methods and if claim scope is narrow or overly broad.
5. What strategic considerations should a licensee or licensee have?
Monitoring patent family filings, challenging validity if necessary, and considering formulation or use claim expansions through continuations or new applications.
References
- U.S. Patent and Trademark Office. (2017). Patent No. 9,636,319.
- European Patent Office. (n.d.). Patent family members.
- PatentScope. (n.d.). Patent filings and issuance data.
- Merges, R. P., & Nelson, R. R. (2020). Patent Law and Policy. Harvard University Press.
- World Intellectual Property Organization. (n.d.). Patent landscape reports.
More… ↓
⤷ Start Trial
|
